What FDA Reviewers Concluded
FDA scientists have told an advisory panel that they cannot verify the central efficacy results of the trial supporting an experimental melanoma therapy, setting up a contested review of a drug the agency has already declined to approve twice.
The therapy is RP1, or vusolimogene oderparepvec, developed by Replimune. It is an oncolytic immunotherapy built from a herpes simplex virus strain, injected directly into tumors and given alongside Bristol Myers Squibb's nivolumab. The proposed use is for adults with advanced melanoma that has progressed after treatment with an anti-PD-1 therapy.
In briefing documents released July 28 ahead of the advisory committee meeting, reviewers wrote that the application does not include an adequate and well-controlled investigation demonstrating substantial evidence of effectiveness. They said the method used to assess tumor response in the trial "confounds interpretation of the reported efficacy results and limits FDA's ability to verify" them.
Replimune shares fell roughly 30 percent after the documents were published. The company said it looked forward to "a constructive dialogue about RP1's clinical meaningfulness."
The Contribution of Effect Problem in Plain Terms
The scientific dispute is narrower than it may appear, and it is worth understanding because it recurs across cancer drug reviews.
RP1 was tested together with nivolumab, in a trial with no comparison group. Nivolumab is an established melanoma drug that produces responses on its own in some patients, including some who previously progressed on similar treatment. When two active agents are given together, and no one receives only one of them, there is no direct way to determine how much of the benefit came from which component.
Regulators call this the contribution-of-effect problem. It is the reason single-arm combination trials are difficult to interpret even when the overall results look encouraging.
Reviewers also said the objective response data from the single-arm trial are not of sufficient magnitude to overcome their concerns, and that without a reliable historical comparison they could not separate a genuine systemic anti-cancer effect from the local effect of injecting a tumor directly.
This is a question about study design and evidence, not about safety. Safety has not been the central objection across the three reviews.
Where the Company and the Agency Disagree on the Numbers
The most consequential detail is that the two sides do not agree on the results themselves.
The IGNYTE trial enrolled 140 patients with advanced melanoma who had confirmed progression on an anti-PD-1 regimen. Replimune has reported an objective response rate of about 33.6 percent and a median duration of response of 24.8 months. Longer-term data presented at a 2026 oncology meeting reported that 47.8 percent of treated patients were alive at three years, rising to 83.5 percent among those who responded.
The FDA's own reanalysis produced substantially different figures. Applying its preferred response criteria, the agency calculated a response rate of 15.7 percent and a median duration of response of 14.1 months.
That gap is the heart of the matter. Reviewers attributed it to response assessment methods they said artifactually inflated the trial's primary objectives and response rates. A reader should note that the difference does not arise from different patients, but from different rules for deciding what counts as a response.
The survival figures carry their own limitation. In a trial without a control group, the observation that responders live longer than non-responders is expected regardless of whether the added drug works, because patients whose cancer responds to any treatment tend to do better.
What This Means for Patients With Few Options
Melanoma is the fifth most common cancer in the United States, with roughly 112,000 new cases estimated for 2026 and about 8,500 deaths annually. Roughly half of patients treated with immune checkpoint blockade will not respond or will eventually progress.
For that group, options are genuinely limited, and the FDA has acknowledged the unmet need in this population. Patients and families following this application should understand what is and is not at stake. RP1 is investigational and not available by prescription. Approval, if it came, would be accelerated approval, meaning the therapy could reach patients while a confirmatory trial continues.
That confirmatory trial, IGNYTE-3, is already underway with a target of about 400 patients and compares the combination against a physician's choice of treatment. Most patients in the comparison group are receiving a nivolumab-and-relatlimab combination.
Patients who want to discuss the therapy should ask an oncologist about eligibility for IGNYTE-3 or other trials rather than waiting on the regulatory outcome. Clinical trial participation, not the August decision, is the realistic near-term route to access. No one should delay an available treatment while waiting for a regulatory decision.
What Happens Next
The advisory committee meets July 30 to consider whether the trial data are evaluable and clinically meaningful. That vote is non-binding. The agency's decision date is August 2, an unusually short interval that leaves little time between the panel's input and the ruling.
The application has been rejected twice, with complete response letters issued in July 2025 and April 2026. Replimune has said a different FDA review team was assigned to the second resubmission. The therapy holds breakthrough therapy designation and priority review.
Several things remain unresolved. The committee had not voted at the time of writing. The agency has not indicated whether it will follow the panel. And whether the confirmatory trial will resolve the contribution-of-effect question is not yet established, though the agency has previously agreed that a comparison within that trial could address it.
The confirmed fact is that FDA reviewers cannot verify the reported efficacy results. The most affected group is patients with melanoma that has progressed after checkpoint blockade. The most reasonable action is a conversation with an oncologist about trial eligibility. The central uncertainty is whether the added therapy contributes benefit beyond its partner drug. The next expected development is the FDA decision on or about August 2.
Developing Story Timeline
July 30, 2026: Advisory committee convenes to review the application. No vote recorded at time of writing.
July 28, 2026: FDA briefing documents released, stating reviewers cannot verify reported efficacy results. Company shares fall roughly 30 percent.
June 26, 2026: FDA accepts third submission as a complete class 1 response and sets an August 2 decision date.
April 10, 2026: FDA issues a second complete response letter.
July 22, 2025: FDA issues the first complete response letter.
Frequently Asked Questions
What is RP1? An investigational oncolytic immunotherapy made from an engineered herpes simplex virus, injected into tumors and given with nivolumab. It is not approved or available by prescription.
What is the contribution of effect problem? When two active drugs are given together with no comparison group, there is no direct way to determine how much benefit came from each one.
Why do the company and the FDA report different response rates? They applied different rules for assessing tumor response. The company reported about 33.6 percent; the agency's reanalysis produced 15.7 percent.
Is this a safety concern? No. The dispute concerns evidence and trial design. Safety has not been the central objection in any of the three reviews.
Can patients get RP1 now? Not by prescription. Patients should ask an oncologist about the ongoing IGNYTE-3 trial or other studies.
What does accelerated approval mean? It allows a therapy to reach patients based on promising early measures while a confirmatory trial continues, with the possibility of withdrawal if that trial fails.
When will the FDA decide? The target decision date is August 2, 2026, three days after the advisory committee meeting.
